|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.48 USD | -0.09% |
|
0.00% | -0.32% |
| Jan. 12 | Avadel Pharmaceuticals Shareholders Approve Buyout by Alkermes | MT |
| Dec. 18 | Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from NASDAQ Biotechnology Index | CI |
| Capitalization | 2.11B 1.82B 1.69B 1.58B 2.93B 191B 3.15B 19.46B 7.66B 91.15B 7.91B 7.75B 334B | P/E ratio 2025 * |
78.5x | P/E ratio 2026 * | 27x |
|---|---|---|---|---|---|
| Enterprise value | 2.02B 1.74B 1.62B 1.51B 2.81B 183B 3.01B 18.66B 7.34B 87.37B 7.59B 7.43B 321B | EV / Sales 2025 * |
7.28x | EV / Sales 2026 * | 5.37x |
| Free-Float |
95.23% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Avadel Pharmaceuticals plc
| 1 day | -0.09% | ||
| Current month | -0.32% | ||
| 1 month | +0.28% | ||
| 3 months | +41.69% | ||
| 6 months | +106.94% | ||
| Current year | -0.32% |
| 1 week | 21.45 |  | 21.6 |
| 1 month | 21.36 | | 21.68 |
| Current year | 21.4 | | 21.6 |
| 1 year | 6.38 | | 23.57 |
| 3 years | 6.38 | | 23.57 |
| 5 years | 6.38 | | 23.57 |
| 10 years | 6.38 | | 23.57 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 59 | 2019-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 61 | 2019-12-01 |
Jerad Seurer
CMP | Compliance Officer | 53 | 2020-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Gregory Divis
BRD | Director/Board Member | 59 | 2019-06-02 |
Peter Thornton
BRD | Director/Board Member | 61 | 2017-06-30 |
Geoffrey Glass
CHM | Chairman | 52 | 2018-11-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | 0.00% | +163.24% | - | 2.11B | |
| -3.76% | -4.81% | +38.33% | +188.75% | 961B | |
| +0.47% | +6.72% | +51.46% | +27.39% | 527B | |
| -2.32% | -3.29% | +26.50% | +41.82% | 392B | |
| +0.46% | +2.22% | +31.25% | +18.51% | 368B | |
| -2.23% | -1.39% | +31.95% | +20.33% | 299B | |
| -1.36% | +0.77% | +27.04% | +35.48% | 279B | |
| -0.04% | -0.02% | +10.87% | +0.47% | 276B | |
| -3.45% | -0.33% | -38.34% | -22.02% | 262B | |
| +0.32% | -0.02% | +22.72% | +22.50% | 177B | |
| Average | -1.08% | +0.38% | +36.50% | +37.03% | 354.28B | |
| Weighted average by Cap. | -1.58% | +0.04% | +28.29% | +65.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 278M 239M 223M 207M 386M 25.09B 414M 2.56B 1.01B 12B 1.04B 1.02B 44.01B | 359M 309M 288M 268M 499M 32.44B 535M 3.31B 1.3B 15.51B 1.35B 1.32B 56.9B |
| Net income | 19.29M 16.61M 15.48M 14.4M 26.8M 1.74B 28.74M 178M 70M 833M 72.32M 70.84M 3.06B | 80.79M 69.59M 64.86M 60.34M 112M 7.3B 120M 745M 293M 3.49B 303M 297M 12.8B |
| Net Debt | -87.47M -75.35M -70.22M -65.32M -122M -7.9B -130M -807M -317M -3.78B -328M -321M -13.86B | -182M -157M -146M -136M -252M -16.42B -271M -1.68B -659M -7.85B -681M -667M -28.79B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-15 | 21.48 $ | -0.09% | 3,744,209 |
| 26-01-14 | 21.50 $ | +0.09% | 1,834,054 |
| 26-01-13 | 21.48 $ | -0.09% | 2,574,082 |
| 26-01-12 | 21.50 $ | 0.00% | 3,555,285 |
| 26-01-09 | 21.50 $ | +0.09% | 1,989,929 |
Delayed Quote Nasdaq, January 15, 2026 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AVDL Stock
Select your edition
All financial news and data tailored to specific country editions
